PMC:7283670 / 55410-56354 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T201","span":{"begin":542,"end":547},"obj":"Body_part"},{"id":"T202","span":{"begin":885,"end":889},"obj":"Body_part"}],"attributes":[{"id":"A201","pred":"fma_id","subj":"T201","obj":"http://purl.org/sig/ont/fma/fma9576"},{"id":"A202","pred":"fma_id","subj":"T202","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T133","span":{"begin":542,"end":547},"obj":"Body_part"}],"attributes":[{"id":"A133","pred":"uberon_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"}],"text":"Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T339","span":{"begin":78,"end":86},"obj":"Disease"},{"id":"T340","span":{"begin":119,"end":127},"obj":"Disease"}],"attributes":[{"id":"A339","pred":"mondo_id","subj":"T339","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A340","pred":"mondo_id","subj":"T340","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T536","span":{"begin":139,"end":141},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T537","span":{"begin":346,"end":347},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T538","span":{"begin":542,"end":547},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"},{"id":"T539","span":{"begin":582,"end":587},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T540","span":{"begin":883,"end":889},"obj":"http://purl.obolibrary.org/obo/CL_0000084"}],"text":"Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T65175","span":{"begin":32,"end":35},"obj":"Chemical"},{"id":"T42271","span":{"begin":94,"end":97},"obj":"Chemical"},{"id":"T66","span":{"begin":166,"end":171},"obj":"Chemical"},{"id":"T5227","span":{"begin":184,"end":187},"obj":"Chemical"},{"id":"T89603","span":{"begin":200,"end":208},"obj":"Chemical"},{"id":"T64472","span":{"begin":265,"end":280},"obj":"Chemical"},{"id":"T16097","span":{"begin":265,"end":274},"obj":"Chemical"},{"id":"T79085","span":{"begin":275,"end":280},"obj":"Chemical"},{"id":"T84596","span":{"begin":297,"end":300},"obj":"Chemical"},{"id":"T22462","span":{"begin":361,"end":366},"obj":"Chemical"},{"id":"T20379","span":{"begin":376,"end":384},"obj":"Chemical"},{"id":"T7585","span":{"begin":442,"end":457},"obj":"Chemical"},{"id":"T86024","span":{"begin":442,"end":451},"obj":"Chemical"},{"id":"T48066","span":{"begin":452,"end":457},"obj":"Chemical"},{"id":"T54548","span":{"begin":588,"end":595},"obj":"Chemical"}],"attributes":[{"id":"A69419","pred":"chebi_id","subj":"T65175","obj":"http://purl.obolibrary.org/obo/CHEBI_145500"},{"id":"A51503","pred":"chebi_id","subj":"T42271","obj":"http://purl.obolibrary.org/obo/CHEBI_145500"},{"id":"A42427","pred":"chebi_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A72432","pred":"chebi_id","subj":"T5227","obj":"http://purl.obolibrary.org/obo/CHEBI_145500"},{"id":"A83391","pred":"chebi_id","subj":"T89603","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A74762","pred":"chebi_id","subj":"T64472","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A30881","pred":"chebi_id","subj":"T16097","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A41384","pred":"chebi_id","subj":"T79085","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A27764","pred":"chebi_id","subj":"T84596","obj":"http://purl.obolibrary.org/obo/CHEBI_145500"},{"id":"A49896","pred":"chebi_id","subj":"T22462","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A81107","pred":"chebi_id","subj":"T20379","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A27789","pred":"chebi_id","subj":"T7585","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A96916","pred":"chebi_id","subj":"T86024","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A13695","pred":"chebi_id","subj":"T48066","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A80547","pred":"chebi_id","subj":"T54548","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"}],"text":"Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020"}

{"project":"LitCovid-sentences","denotations":[{"id":"T607","span":{"begin":0,"end":352},"obj":"Sentence"},{"id":"T608","span":{"begin":353,"end":493},"obj":"Sentence"},{"id":"T609","span":{"begin":494,"end":561},"obj":"Sentence"},{"id":"T610","span":{"begin":562,"end":674},"obj":"Sentence"},{"id":"T611","span":{"begin":675,"end":798},"obj":"Sentence"},{"id":"T612","span":{"begin":799,"end":944},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1879","span":{"begin":832,"end":835},"obj":"Gene"},{"id":"2095","span":{"begin":78,"end":86},"obj":"Disease"},{"id":"2096","span":{"begin":119,"end":127},"obj":"Disease"}],"attributes":[{"id":"A1879","pred":"tao:has_database_id","subj":"1879","obj":"Gene:1401"},{"id":"A2095","pred":"tao:has_database_id","subj":"2095","obj":"MESH:C000657245"},{"id":"A2096","pred":"tao:has_database_id","subj":"2096","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)\nControl group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption\nSecondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score\nOther outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020"}